We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab (RESPONDER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03263039
Recruitment Status : Active, not recruiting
First Posted : August 28, 2017
Last Update Posted : August 20, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
M.P.J.K. Lolkema, Erasmus Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 19, 2022
Estimated Study Completion Date : August 19, 2023
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 December 15, 2022
 
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):